Detecting EGFR T790M Mutations From Circulating Tumor Cells
The purpose of this research study is to determine if the EGFR mutation can be detected in CTCs. CTCs are cancer cells that are shed from solid tumors and float freely in the bloodstream. A device called the CTC-chip has been developed to find CTCs in the blood of patients with cancer. This is an experimental device. Using this device, the investigators will test participants' blood to try and find CTCs with the EGFR mutation and compare them with the results from the biopsy your doctor has recommended. The long-term goal of this research is to develop a way to test for the EGFR mutation that is less invasive than a tumor biopsy.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Detecting EGFR T790M Mutations From Circulating Tumor Cells|
- Number of patients with detectable EGFR mutations in their CTCs [ Time Frame: 2 years ] [ Designated as safety issue: No ]Calculate the number of patients in the study population with detectable EGFR mutations in the CTCs in order to demonstrate the feasibility of testing for EGFR mutations from captured CTCs
- Number of patients with CTC-derived EGFR genotyping matching their tumor-derived EGFR genotyping [ Time Frame: 2 yearss ] [ Designated as safety issue: No ]Determine the concordance of EGFR genotyping from CTCs compared to tumor tissue
- Number of patients with EGFR gentoype results detectable from plasma cfDNA [ Time Frame: 2 years ] [ Designated as safety issue: No ]Explore the feasibility of EGFR genotyping from plasma circulating free DNA (cfDNA)
Biospecimen Retention: Samples With DNA
Circulating Tumor Cells (CTCs)
|Study Start Date:||November 2012|
|Estimated Primary Completion Date:||November 2014 (Final data collection date for primary outcome measure)|
Subjects with advanced NSCLC, will undergo blood draw
Device: Circulating tumor cell chip
three tubes (6 teaspoons) of peripheral blood are drawn and are analyzed using the CTC chip
Other Name: Herringbone circulating tumor cell chip, herringbone CTC chip, HBCTC chip
In order to participate in this study you need to have a diagnosis of NSCLC that has spread or is unable to be surgically removed. In addition, your cancer must have an EGFR mutation and you must have a scheduled (or recently performed) biopsy to check on the presence of any other mutations related to targeted drug resistance.
After you sign consent to participate in this study we will draw a blood sample (three tubes of blood). This is about 6 teaspoons of blood.
The number of CTCs in your blood will not be reported to you since it is not known if this number has any meaning or if it impacts your medical care in any way. These results will not become part of your medical record. They will be kept in a separate, secure location.
We will collect information from your medical records and store it in a research record that we create about you. The study team will use this information to compare details about your medical history with the results of the experiments done on your blood.
Genetic material (DNA) will be removed from the CTCs found in your blood. This genetic material will be stored at the Massachusetts General Hospital and studied along with samples from other participants on this research study. Your samples will not be labeled with your name or any information that identifies you. Your samples will have a study-specific code number on them. The code linking your name to the sample will be kept in a secure location, available only to the investigators of the study and select study team members.
After the blood draw we will follow your status every 6 months by reviewing your medical records.
|Contact: Lecia Sequist, MD, MPHfirstname.lastname@example.org|
|United States, Massachusetts|
|Massachusetts General Hospital||Recruiting|
|Boston, Massachusetts, United States, 02115|
|Contact: Lecia Sequist, MD, MPH 617-724-4000 email@example.com|
|Principal Investigator: Lecia Sequist, MD|
|Dana-Farber Cancer Institute||Recruiting|
|Boston, Massachusetts, United States, 02215|
|Contact: Pasi Janne, MD, PhD 617-632-6036 firstname.lastname@example.org|
|Principal Investigator: Pasi Janne, MD, PhD|
|United States, New York|
|Memorial Sloan Kettering Cancer Center||Recruiting|
|New York, New York, United States, 10065|
|Contact: Greg Riely, MD 212-639-2000 email@example.com|
|Principal Investigator: Greg Riely, MD|
|United States, Texas|
|MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: John Heymach, MD, PhD 713-792-6363 firstname.lastname@example.org|
|Principal Investigator: John Heymach, MD, PhD|